Dr. Hoover, a Director in the Biotechnology/Chemical Group, has firsthand understanding of his clients’ intellectual property and business needs and how they are impacted by an increasingly competitive marketplace.  His practice focuses on the strategic evaluation, creation, protection, and leveraging of IP assets.  He specializes in corporate intellectual property and provides counsel on matters relating to: product driven portfolio, lifecycle, and risk management; IP asset transfer and licensing; preparing for, conducting, and defending IP-related due diligence inquiries; and patentability, freedom to operate, validity, and infringement issues.  Dr. Hoover also has extensive domestic and foreign patent prosecution experience and has prosecuted nearly 500 U.S. patents to issuance, alone.